Showing 2271-2280 of 7604 results for "".
Enduring Success
https://practicaldermatology.com/topics/practice-management/enduring-success/20672/Make sure your practice does everything it can to satisfy and retain employees.Itch Be Gone
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/itch-be-gone/18524/Could botulinum toxins be the answer for non-histaminergic itch? Erin Gilbert, MD discusses her research in this area and results she's seen to date.Beyond SPF: Protecting the Skin
https://practicaldermatology.com/topics/skin-cancer-photoprotection/beyond-spf-protecting-the-skin-/18535/In addition to protecting the skin from sun damage, it's becoming increasingly important to consider pollution's role in skin aging. Arianne Shadi Kourosh, MD, and Rebecca Kazin, MD discuss the need for a well tailored regimen and what to look for in sun protection, barrier protection, cleaners, anEnbrel Gets Nod for Pediatric PsO; IL-33 Targeted in Itch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-enbrel-gets-nod-for-pediatric-pso-il-33-targeted-in-itch/18562/FDA approved Amgen's Enbrel (etanercept) for chronic moderate to severe psoriasis in pediatric patients age 4 to 17. DermCheck App partners with anti-bullying groups Pacer and Not In My Town to help fight bullying and expand acne care. Researchers show that anti-IL-33 antibody reduces itch of poisonElections and Markets, Encore and Biofrontera Launches, More
https://practicaldermatology.com/topics/practice-management/dermwiretv-elections-and-markets-encore-and-biofrontera-launches-more/18564/Election years bring market uncertainty, but should you be making any changes to your portfolio now? Financial experts weigh in on why—no matter the results—there's no need for panic. Allergan launches a new campaign, ActuallySheCan, to empower young women. Several new products are now available forAllergan Acquires Vitae, PsA Day, Novan News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-acquires-vitae-psa-day-novan-news/18572/Allergan is acquiring clinical-stage biotechnology company Vitae Pharmaceuticals for $21.00 per share, in cash, for a total transaction value of approximately $639 million. Novan has launched its initial public offering and is now listed on the NASDAQ. Celgene Corporation and the National PsoriasisImproving Outcomes with Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/improving-outcomes-with-fillers/18740/For the most optimal outcomes when injecting fillers, Dr. Galadari says there are three essential steps: choose the right patient, choose the right filler, and choose the right injection technique. He shares his favorite types of fillers for specific areas and discusses when and why he uses a cannulDoctors Betrayed by Traditional Financial Strategies, Part 2
https://practicaldermatology.com/topics/practice-management/doctors-betrayed-by-traditional-financial-strategies-part-2/20939/Helpful hints to avoid tax, investment, and insurance mistakes that can be made if you follow advice designed for tens of millions of average Americans.Decisions, Decisions...
https://practicaldermatology.com/topics/practice-management/decisions-decisions/20969/What it means to be a dermatologist is changing. Are you ready?What's New in Topical Acne Therapy
https://practicaldermatology.com/topics/practice-management/whats-new-in-topical-acne-therapy/21105/From new approvals to a growing pipeline, the outlook is bright for the continued refinement of topical acne therapy.